The FDA approved Guardant Health's Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's Hernexeos, a targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer. The approval expands the clinical utility of Guardant's test and supports adoption alongside a new oncology treatment. The news is positive for Guardant Health, but the immediate market impact should be limited to the stock and broader diagnostics/biotech space.
The FDA approved Guardant Health's Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's Hernexeos, a targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer. The approval expands the clinical utility of Guardant's test and supports adoption alongside a new oncology treatment. The news is positive for Guardant Health, but the immediate market impact should be limited to the stock and broader diagnostics/biotech space.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
